Pharmaceuticals, Biotechnology and Life Sciences
Pfizer’s 20vPnC vaccine candidate in Pahse 3 study showed responses elicited by 20vPnC for all 20 serotypes equivalent across all three lots, meeting the primary immunogenicity objective of the study.
Novavax said Monday that the Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $384 million of additional funding, on top of $4 million it invested in March, to advance clinical development of NVX-CoV2373, Novavax’ coronavirus vaccine candidate against SARS-CoV-2.
First participants have been dosed at NYU Grossman School of Medicine and University of Maryland School of Medicine.
Moderna has engaged with Lonza to work on its novel coronavirus vaccine, with a goal to enable manufacturing of up to 1 billion doses per year, noting that technology transfer is expected to begin in June 2020.
Moderna has submitted IND to USFDA for 600 participant Phase 2 study to continue from ongoing NIH-led Phase 1 study, as planning underway for Phase 3 study expected to begin in the fall of 2020.
MigVax is getting an investment of $12 million to accelerate path to clinical trials and bring Israel’s human coronavirus vaccine to market, as it pioneers the effort to develop Israel’s human vaccine against COVID-19.
N4 Pharma will test a Covid-19 DNA plasmid if Nuvec, a novel delivery system for cancer treatments and vaccines, can be used as a delivery system by potential collaboration partners developing Covid-19 DNA or RNA vaccines.
Vaxess and GC Pharma will collaborate on Influenza vaccine smart release patch, in a deal which will give Vaxess exclusive…
Agreement targets the development of a cross-reactive vaccine to protect against the most virulent enteroviruses, including enterovirus 71 (EV71)
Sanofi’s MenQuadfi Meningococcal Polysaccharide Tetanus Toxoid Conjugate Vaccine candidate to help prevent meningococcal meningitis will be reviewed for BLA by the FDA, expecting to reach the decision on April 25, 2020.